Form4insider filings, from the source

SEC Form 4 · accession 0001562180-19-000146

Sienna Biopharmaceuticals, Inc. · SNNA

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner
III Frederick Beddingfield
Officer — President & CEO · Director
Period of report
Jan 1, 2019
Accepted (ET)
Jan 3, 2019 · 6:11 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001656328

Table I — non-derivative securities

SecurityDateCodeSharesPriceA/DOwned afterD/INature of ownership
Common StockF1,F2Jan 1, 2019A187,500—A791,662D
Common StockF3holding———112,614ISee Footnote

Table II — derivative securities

SecurityConv. / exercise priceDateCodeSharesA/DExercisableExpiresUnderlyingUnderlying sharesOwned afterD/I
Stock Options (Right to buy)$2.32Jan 1, 2019A40,968AJan 1, 2019Jan 1, 2029Common Stock40,96840,968D
Stock Options (Right to buy)F4$2.32Jan 1, 2019A93,750A—Jan 1, 2029Common Stock93,75093,750D
Stock Options (Right to buy)F5$2.32Jan 1, 2019A93,750A—Jan 1, 2029Common Stock93,750187,500D

Explanation of responses